Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۵۰۰ • واحد: mg/L

حداقل ۱۰ — حداکثر ۶۰ • واحد: g/L

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mgps score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Score 00–0
  • Score 11–1
  • Score 22–2
Direct Clinical Answer

The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include crp level. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status

Clinical Indication

The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is indicated for bedside clinical practice to support Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Should be interpreted in context of cancer stage, treatment status, and other prognostic factors.

Formula & Variables:

Score determined by CRP and albumin levels. Score 0: CRP ≤10 mg/L (any albumin). Score 1: CRP >10 mg/L and albumin ≥35 g/L. Score 2: CRP >10 mg/L and albumin <35 g/L.

Input Parameters

NameTypeRequiredDescription
crp_levelfloatYesC-Reactive Protein (CRP) level(mg/L)
albumin_levelfloatYesSerum albumin level(g/L)

Score Interpretation & Guidance

RangeStageDescription
0–0Score 0Good prognosis
1–1Score 1Intermediate prognosis
2–2Score 2Poor prognosis

Evidence-Based References (EBM)

  • Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011 Aug 23;105(5):726-34. doi: 10.1038/bjc.2011.292.DOI: 10.1038/bjc.2011.292
  • McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013 Aug;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003.DOI: 10.1016/j.ctrv.2012.08.003
  • Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003 Aug 4;89(3):477-81. doi: 10.1038/sj.bjc.6601242.DOI: 10.1038/sj.bjc.6601242

Related calculators